Current concepts in tumor imaging with whole-body MRI with diffusion imaging (WB-MRI-DWI) in multiple myeloma and lymphoma

被引：32

作者：

Stecco, Alessandro ^{[1
]}

Buemi, Francesco ^{[2
]}

Iannessi, Antoine ^{[3
]}

Carriero, Alessandro ^{[1
]}

Gallamini, Andrea ^{[4
]}

机构：

[1] Azienda Ospedal Univ Maggiore Carita, Serv Diag & Therapies Dept Radiol, Cso Mazzini 18, I-28100 Novara, Italy

[2] Azienda Osped Osped Riuniti Papardo Piemonte, Radiol Dept, Messina, Italy

[3] Ctr Antoine Lacassagne, Radiol Dept, Nice, France

[4] Ctr Antoine Lacassagne, Res Innovat & Stat Dept, Nice, France

来源：

LEUKEMIA & LYMPHOMA | 2018年 / 59卷 / 11期

关键词：

Multiple myeloma; lymphoma; imaging; MRI; whole-body MRI; diffusion-weighted imaging; therapeutic response; STEM-CELL TRANSPLANTATION; NON-HODGKIN-LYMPHOMA; UNDETERMINED SIGNIFICANCE MGUS; POSITRON-EMISSION-TOMOGRAPHY; MINIMAL RESIDUAL DISEASE; CLINICAL STAGING SYSTEM; 1ST COMPLETE REMISSION; MONOCLONAL GAMMOPATHY; RESPONSE ASSESSMENT; WEIGHTED MRI;

D O I：

10.1080/10428194.2018.1434881

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Whole-body MRI (WB-MRI) with diffusion-weighted imaging (DWI) can now be used to stage and restage multiple myeloma (MM) and lymphoma. Magnetic resonance imaging (MRI) is the standard tool to detect BM involvement (BMI). The 2016 diagnostic criteria of the International Myeloma Working Group identify WB-MRI and fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) as the most sensitive imaging techniques for detecting skeletal and extra-skeletal MM invasion, respectively. Preliminary findings have also shown that WB-MRI is better than CT and equal to PET/CT in staging aggressive lymphoma and Hodgkin lymphoma, whereas MRI is better for diagnosing BMI in patients with low-grade lymphoma. Signal intensity (SI) and the apparent diffusion coefficient (ADC) are useful metrics to quantify the chemotherapy response in WB-MRI.

引用

页码：2546 / 2556

页数：11

共 110 条

[1] Whole-body diffusion-weighted imaging compared with FDG-PET/CT in staging of lymphoma patients [J].

Abdulqadhr, Goran ;

Molin, Daniel ;

Astrom, Gunnar ;

Suurkula, Madis ;

Johansson, Lars ;

Hagberg, Hans ;

Ahlstrom, Hakan .

ACTA RADIOLOGICA, 2011, 52 (02) :173-180

[2] Comparison between whole-body MRI with diffusion-weighted imaging and PET/CT in staging newly diagnosed FDG-avid lymphomas. [J].

Albano, Domenico ;

Patti, Caterina ;

La Grutta, Ludovico ;

Agnello, Francesco ;

Grassedonio, Emanuele ;

Mule, Antonino ;

Cannizzaro, Giorgio ;

Ficola, Umberto ;

Lagalla, Roberto ;

Midiri, Massimo ;

Galia, Massimo .

EUROPEAN JOURNAL OF RADIOLOGY, 2016, 85 (02) :313-318

[3] Diffusion-Weighted Magnetic Resonance Imaging as a Cancer Biomarker: Consensus and Recommendations [J].

不详 .

NEOPLASIA, 2009, 11 (02) :102-125

[4] Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma [J].

Attal, Michel ;

Lauwers-Cances, Valerie ;

Marit, Gerald ;

Caillot, Denis ;

Moreau, Philippe ;

Facon, Thierry ;

Stoppa, Anne Marie ;

Hulin, Cyrille ;

Benboubker, Lofti ;

Garderet, Laurent ;

Decaux, Olivier ;

Leyvraz, Serge ;

Vekemans, Marie-Christiane ;

Voillat, Laurent ;

Michallet, Mauricette ;

Pegourie, Brigitte ;

Dumontet, Charles ;

Roussel, Murielle ;

Leleu, Xavier ;

Mathiot, Claire ;

Payen, Catherine ;

Avet-Loiseau, Herve ;

Harousseau, Jean-Luc .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (19) :1782-1791

[5] Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group [J].

Barrington, Sally F. ;

Mikhaeel, N. George ;

Kostakoglu, Lale ;

Meignan, Michel ;

Hutchings, Martin ;

Mueeller, Stefan P. ;

Schwartz, Lawrence H. ;

Zucca, Emanuele ;

Fisher, Richard I. ;

Trotman, Judith ;

Hoekstra, Otto S. ;

Hicks, Rodney J. ;

O'Doherty, Michael J. ;

Hustinx, Roland ;

Biggi, Alberto ;

Cheson, Bruce D. .

JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (27) :3048-+

[6] Magnetic resonance imaging as a supplement for the clinical staging system of Durie and Salmon? [J].

Baur, A ;

Stäbler, A ;

Nagel, D ;

Lamerz, R ;

Bartl, R ;

Hiller, E ;

Wendtner, C ;

Bachner, F ;

Reiser, M .

CANCER, 2002, 95 (06) :1334-1345

[7] High risk of subsequent neoplasms continues with extended follow-up of childhood Hodgkin's disease: Report from the late effects study group [J].

Bhatia, S ;

Yasui, Y ;

Robison, LL ;

Birch, JM ;

Bogue, MK ;

Diller, L ;

DeLaat, C ;

Fossati-Bellani, F ;

Morgan, E ;

Oberlin, O ;

Reaman, G ;

Ruymann, FB ;

Tersak, J ;

Meadows, AT .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (23) :4386-4394

[8]

Caldarella Carmelo, 2012, Int J Mol Imaging, V2012, P175803, DOI 10.1155/2012/175803

[9] Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study [J].

Cavo, Michele ;

Tacchetti, Paola ;

Patriarca, Francesca ;

Petrucci, Maria Teresa ;

Pantani, Lucia ;

Galli, Monica ;

Di Raimondo, Francesco ;

Crippa, Claudia ;

Zamagni, Elena ;

Palumbo, Antonio ;

Offidani, Massimo ;

Corradini, Paolo ;

Narni, Franco ;

Spadano, Antonio ;

Pescosta, Norbert ;

Deliliers, Giorgio Lambertenghi ;

Ledda, Antonio ;

Cellini, Claudia ;

Caravita, Tommaso ;

Tosi, Patrizia ;

Baccarani, Michele .

LANCET, 2010, 376 (9758) :2075-2085

[10] The importance of bone marrow examination in determining complete response to therapy in patients with multiple myeloma [J].

Chee, Cheng E. ;

Kumar, Shaji ;

Larson, Dirk R. ;

Kyle, Robert A. ;

Dispenzieri, Angela ;

Gertz, Morie A. ;

Colby, Colin L. ;

Rajkumar, S. Vincent .

BLOOD, 2009, 114 (13) :2617-2618

← 1 2 3 4 5 6 7 8 9 10 →